| Trial ID | NCT07340554 |
| Status | Recruiting |
| Condition | Cannabis Use |
| Intervention | Contingency Management |
This trial addresses a critical gap in adolescent cannabis treatment by investigating neurobiological predictors of treatment response. Understanding brain-based markers that predict which teens will benefit most from contingency management could enable personalized treatment approaches during this vulnerable developmental period.
This observational study enrolls teens aged 14-17 who use cannabis and employs neuroimaging to examine brain activity patterns related to learning and reward processing. Participants undergo fMRI scanning before entering a 10-week virtual contingency management program that provides incentives for cannabis abstinence, verified through home-based urine testing. The primary endpoint is identifying neural predictors of treatment response, while secondary measures include cannabis use reduction and sustained abstinence rates.
“If this research identifies reliable neuroimaging biomarkers, I could potentially use brain-based assessments to guide treatment selection for adolescent patients, moving beyond trial-and-error approaches to more precise, individualized care strategies.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
This trial item was assembled from normalized source metadata and pipeline scoring.
